← Leaderboards
Runhua Runa Liu
University Of Alabama At Birmingham
$2,517,658
Attributed
$5,387,094
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,387,094 · 4
By mechanism
R01$5,182,906 · 3
R56$204,188 · 1
Top collaborators
- Xiaoguang Margaret Liu11 shared
- Lizhong Wang5 shared
- Jiangbing Zhou3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Xiaoguang Margaret Liu$3,757,363
- Edward E Partridge$43,798,134
- Michael S. Saag$146,765,034
- Isabel C Scarinci$19,061,797
- Lizhong Wang$2,698,472
Others in their field
Other Emerging Leaders on “Neoplastic Cell”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Zachary Scott Morris · University Of Wisconsin-Madison$6,108,830
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$6,006,178
- Gordon M Ringold · Quadriga Biosciences, Inc.$5,755,369
- Himisha Beltran · Dana-Farber Cancer Inst$5,409,904
Research focus
Neoplastic CellXenograft ModelIn VivoEffective TherapyTumorXenograft ProcedureTargeted TreatmentMalignant Breast NeoplasmTreatment StrategyMonoclonal AntibodiesSmall MoleculeSystemic ToxicityPharmaceutical PreparationsSamplingOverexpressionCellsChemotherapyBreast Cancer PatientTriple-Negative Invasive Breast CarcinomaBreast Cancer CellMediatingOperative Surgical ProceduresExtracellular DomainAntibody-Drug Conjugates
Grant awards (15)
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$85,364
R01 · FY2025 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$462,863
R01 · FY2024 · CA · contact PI
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$364,267
R01 · FY2024 · CA · contact PI
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$322,710
R01 · FY2024 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$477,479
R01 · FY2023 · CA · contact PI
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$371,500
R01 · FY2023 · CA · contact PI
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$332,900
R01 · FY2023 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$477,479
R01 · FY2022 · CA · contact PI
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$386,974
R01 · FY2022 · CA · contact PI
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$332,900
R01 · FY2022 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$401,859
R01 · FY2021 · CA · contact PI
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$339,694
R01 · FY2021 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$487,223
R01 · FY2020 · CA · contact PI
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$339,694
R01 · FY2020 · CA · contact PI
Utilizing microRNA-146a to Block Triple-Negative Breast Cancer Cell Colonization$204,188
R56 · FY2019 · CA · contact PI